BattellePharma to Present At ASCO Annual Meeting; Results From Phase I Study of Resmycin -- TM -- Inhaled Anti-Cancer Therapy Revealed.Business Editors & Health/Medical Writers BIOWIRE2K COLUMBUS, Ohio--(BW HealthWire)--May 16, 2002 BattellePharma, Inc., formerly Battelle Pulmonary Therapeutics, Inc., today announced it will present preliminary results of a Phase I clinical study targeting lung cancer at the 38th Annual Meeting of the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. (ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company ). The meeting will be held in Orlando, Florida May 18-21, 2002.
Abstract 1204: A multicenter Phase I clinical and
pharmacological study of inhaled doxorubicin (Resmycin) in
adults with advanced solid tumors affecting the lungs. Poster
Display/Discussion: Lung Cancer, Sunday, May 19, 2002, 8:00
a.m. - Noon
Dr. Sunil Sharma, lead investigator of the doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased study from Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New , will present the results of the multi-center Phase I clinical and pharmacologic study of BattellePharma's lead product Resmycin, an inhaled formulation of doxorubicin. The patients included adults with advanced solid lung tumors. The study involved clinicians and scientists at Memorial Sloan Kettering Cancer Center, the Arthur G. James Arthur G. James once said, “All cancer will eventually be wiped out; there’s no doubt about that, I don’t know how long it will take, but… I’m sure that day is coming. Cancer Center, Richard J. Solove Research Institute, Yale University, University of Wisconsin, Vanderbilt University, University of Chicago, Karmanos Cancer Institute, and BattellePharma. The initial indication for Resmycin is expected to be for the treatment of bronchioloalveolar carcinoma (BAC BAC abbr. blood alcohol concentration ), a subset of non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . Resmycin received Fast Track designation by the Food and Drug Administration for BAC that may allow BattellePharma to file a New Drug Application with Phase II data. About BattellePharma BattellePharma is a pre-public specialty pharmaceutical company leveraging science and technology to design more effective medicines. The company has a growing portfolio of nine products in development, with several in early clinical trials. The products are based on three proprietary platforms: Mystic(TM) inhalation technology, novel formulation technologies, and inhaled anticancer therapy. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases and lung cancer. BattellePharma has partnerships with numerous pharmaceutical corporations, including Abbott Laboratories, GlaxoSmithKline, Pfizer Inc, Viasys Healthcare, and ViroPharma Inc, and is a subsidiary of Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , the world's largest independent and private research and development organization. For more information on BattellePharma, reference the company's website at www.battellepharma.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion